Bispecifics Could Be A Threat To CAR-Ts, But Efficacy May Trump Convenience
T-cell-engaging bispecific antibodies emerged at ASH as viable competitors for autologous T-cell therapies, but while their off-the-shelf availability is intriguing, it may be too early to say if their safety and efficacy beats CAR-Ts.
You may also be interested in...
With the first Revlimid generics launching in 2022, Bristol Myers Squibb’s late-stage assets are key, but earlier programs will help fill the void as Opdivo and Eliquis lose exclusivity later in the decade.
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.